Physician profile
Emily Gilbert
NPI 1376091116
$9,732.79
in general payments reported to CMS, 2019-2025
52 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,013 · 2022: $2,152 · 2023: $2,316 · 2024: $1,641 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,387 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,387.42 |
| Education | $179.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,605.88 | 2021-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,468.67 | 2021-2025 | Trelegy Ellipta, Nucala, Ojjaara |
| Novartis Pharmaceuticals Corporation | $873.90 | 2021-2025 | |
| Genzyme Corporation | $692.86 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $685.49 | 2021-2025 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $683.60 | 2021-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $302.47 | 2021-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $299.27 | 2021-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $256.98 | 2022-2025 | Glassia, Fruzaqla, Ninlaro |
| Grifols USA, LLC | $243.90 | 2021-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $203.75 | 2021-2024 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $151.53 | 2024-2025 | |
| Pfizer INC. | $140.79 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $140.58 | 2021-2022 | |
| Tersera Therapeutics LLC | $136.90 | 2024-2025 | Zoladex, Xermelo |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $135.11 | 2024-2025 | Onivyde |
| Abbvie INC. | $128.13 | 2024-2025 | |
| Genentech USA, INC. | $122.32 | 2021-2025 | Polivy, Itovebi, Xolair |
| Amgen INC. | $121.36 | 2023-2025 | Tezspire |
| Pharming Healthcare, INC. | $105.90 | 2023-2024 | Ruconest |
| Janssen Biotech, INC. | $99.00 | 2024 | Darzalex |
| Electromed, INC. | $89.82 | 2021-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $88.76 | 2023-2025 | Keytruda |
| Insmed, INC. | $86.10 | 2021-2023 | Arikayce |
| Daiichi Sankyo INC. | $80.74 | 2025 | Enhertu |
| Baxter Healthcare | $69.77 | 2022 | |
| Eisai INC. | $69.68 | 2025 | |
| Incyte Corporation | $62.57 | 2024-2025 | Jakafi |
| Pharmacosmos Therapeutics INC. | $45.96 | 2024-2025 | Monoferric |
| Deciphera Pharmaceuticals INC. | $41.95 | 2025 | Romvimza, Qinlock |
| Puma Biotechnology, INC. | $40.84 | 2025 | |
| Progenics Pharmaceuticals, INC. | $36.67 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $33.43 | 2021-2022 | |
| Array Biopharma INC | $32.13 | 2025 | Mektovi, Braftovi, Tukysa |
| Taiho Oncology, INC. | $28.84 | 2024 | |
| Karyopharm Therapeutics INC. | $28.38 | 2025 | Xpovio |
| Nabriva Therapeutics, Plc | $27.50 | 2021-2022 | |
| Lilly USA, LLC | $26.78 | 2024 | Verzenio, Jaypirca |
| Sandoz INC. | $24.48 | 2022 | |
| Exelixis INC. | $23.38 | 2025 | Cabometyx |
| Beone Medicines USA, INC. | $18.64 | 2025 | Tevimbra, Brukinsa |
| Adc Therapeutics America, INC. | $18.50 | 2025 | |
| Advanced Respiratory, INC | $17.71 | 2021 | |
| Servier Pharmaceuticals LLC | $17.42 | 2024 | |
| Adaptive Biotechnologies Corporation | $17.26 | 2024 | Clonoseq |
| Stemline Therapeutics INC. | $16.75 | 2024 | Orserdu |
| Actelion Pharmaceuticals US, INC. | $16.54 | 2024 | Opsumit, Uptravi |
| Accord Healthcare, INC. | $15.74 | 2025 | |
| Genmab U.S., INC. | $15.42 | 2025 | Epkinly |
| Acrotech Biopharma INC. | $14.64 | 2025 | Beleodaq |
| Agios Pharmaceuticals, INC. | $14.08 | 2025 | Pyrukynd |
| Hikma Pharmaceuticals USA | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.